FDA Clocks Patent Extension Time for OJEMDA Drug
Published Date: 12/29/2025
Notice
Summary
The FDA has set the official review period for the drug OJEMDA, which helps the company extend its patent and protect their invention longer. This affects the drug maker and anyone tracking patent dates, with deadlines to challenge or comment on these dates by early 2026. It’s a key step to keep innovation alive while making sure the patent system stays fair and on schedule.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 0 costs, 2 mixed.
FDA sets OJEMDA review period length
FDA determined the regulatory review period for OJEMDA (tovorafenib) is 4,942 days total: 4,705 days in the testing phase and 237 days in the approval phase. FDA lists the key dates used: IND effective October 14, 2010; NDA initially submitted August 31, 2023 (NDA 217700); and approval on April 23, 2024.
Applicants seek 5-year patent extension
The applicants (Day One Biopharmaceuticals, Inc. and Viracta Therapeutics, Inc.) seek 5 years of patent-term extension for U.S. Patent No. 8,293,752. FDA notes this determination establishes the maximum potential length, but the USPTO will apply statutory limitations when calculating the actual extension.
Deadlines to challenge or petition dates
Anyone who believes the published dates are wrong may submit comments and request a redetermination by February 27, 2026. Any interested person may petition FDA about whether the applicants acted with due diligence during the regulatory review period by June 29, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17215, Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
2026-17229, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
Previous / Next Documents
Previous: 2025-23865, Determination of Regulatory Review Period for Purposes of Patent Extension; LEQEMBI
The FDA has officially set the review period for LEQEMBI, a new medicine, so its patent can be extended. This helps the company protect their invention longer, which might affect when generic versions can appear. If anyone thinks the dates are wrong or wants to challenge the company’s effort during review, they must act by early 2026.
Next: 2025-23868, Determination of Regulatory Review Period for Purposes of Patent Extension; ZELSUVMI
The FDA has set the official review period for the drug ZELSUVMI, which helps the company extend its patent protection. This means the drug maker could get extra time to keep their invention exclusive, potentially affecting when generic versions can enter the market. People can comment or challenge these dates by early 2026, so stay tuned if you have info to share!